[Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
In most developed countries of the world the basis of the ulcer treatment is formed by H+/K(+)-ATPase blockers: omeprazole, pantoprazole, lansoprazole etc. though in accordance with the Maastricht treaty (2) the first line therapy may also be based upon the application of one of H2-histamine receptor blockers, specifically the two-component ranitidine bismuth citrate preparation.
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D000077402:Pantoprazole; D010295:Parietal Cells, Gastric / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology / Q000648:ultrastructure; D054328:Proton Pump Inhibitors; D013454:Sulfoxides / Q000494:pharmacology
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D013454:Sulfoxides; D064747:Lansoprazole; D000077402:Pantoprazole; D009853:Omeprazole
Submikroskopicheskie aspekty mekhanizma deĭstviia ingibitorov H+/K+-atpazy parietal'nykh kletok zheludka.